According to Zacks, “Ikena Oncology Inc. is focused on developing cancer therapies targeting key signaling pathways which drive the formation and spread of cancer. The company’s product candidates include IK-930, IK-175, IK-412 and IK-007, which are in clinical stage. Ikena Oncology Inc. is based in Boston, United States. “
Several other research firms have also commented on IKNA. Credit Suisse Group cut their price objective on Ikena Oncology from $27.00 to $24.00 in a research report on Thursday, March 17th. HC Wainwright boosted their price target on Ikena Oncology from $25.00 to $26.00 and gave the stock a buy rating in a research report on Wednesday, April 13th.
Ikena Oncology (NASDAQ:IKNA – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.05). On average, analysts expect that Ikena Oncology will post -1.83 earnings per share for the current year.
A number of large investors have recently bought and sold shares of IKNA. Legal & General Group Plc increased its position in shares of Ikena Oncology by 143.9% during the fourth quarter. Legal & General Group Plc now owns 2,273 shares of the company’s stock worth $29,000 after acquiring an additional 1,341 shares during the last quarter. Baystate Wealth Management LLC purchased a new stake in Ikena Oncology during the 4th quarter worth approximately $38,000. Morgan Stanley raised its position in shares of Ikena Oncology by 787.6% in the 3rd quarter. Morgan Stanley now owns 3,231 shares of the company’s stock valued at $41,000 after purchasing an additional 2,867 shares in the last quarter. Nisa Investment Advisors LLC purchased a new position in shares of Ikena Oncology during the 1st quarter valued at approximately $49,000. Finally, Wells Fargo & Company MN acquired a new stake in shares of Ikena Oncology during the second quarter worth approximately $59,000. 67.33% of the stock is owned by institutional investors.
About Ikena Oncology (Get Rating)
Ikena Oncology, Inc, a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.
- Get a free copy of the StockNews.com research report on Ikena Oncology (IKNA)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Analog Devices Is Ready To Scale New Highs Despite Tech Wreck
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.